Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse
| Autor: | Andy I. Chen, Veronika Bachanova, Julie Lisano, Tamás Masszi, Jerzy Holowiecki, Auayporn Nademanee, Patrick J. Stiff, Craig H. Moskowitz, Simonetta Viviani, Connie Lee, Teresa McClendon, Muneer H. Abidi, Anna Sureda, Jan Walewski, John W. Sweetenham, Edward Agura |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male Oncology medicine.medical_specialty Immunoconjugates Adolescent Immunology Placebo Biochemistry 03 medical and health sciences 0302 clinical medicine Recurrence Risk Factors Internal medicine medicine Humans Progression-free survival Risk factor Autografts Child Brentuximab vedotin Survival rate Brentuximab Vedotin business.industry Hazard ratio Hematopoietic Stem Cell Transplantation Cell Biology Hematology Middle Aged Hodgkin Disease Progression-Free Survival Survival Rate Transplantation Clinical trial 030220 oncology & carcinogenesis Female business Follow-Up Studies 030215 immunology medicine.drug |
| Zdroj: | Blood. 132:2639-2642 |
| ISSN: | 1528-0020 0006-4971 |
| DOI: | 10.1182/blood-2018-07-861641 |
| Popis: | The phase 3 AETHERA trial established brentuximab vedotin (BV) as a consolidative treatment option for adult patients with classical Hodgkin lymphoma (cHL) at high risk of relapse or progression after autologous hematopoietic stem-cell transplantation (auto-HSCT). Results showed that BV significantly improved progression-free survival (PFS) vs placebo plus best supportive care alone. At 5-year follow-up, BV continued to provide patients with sustained PFS benefit; 5-year PFS was 59% (95% confidence interval [CI], 51-66) with BV vs 41% (95% CI, 33-49) with placebo (hazard ratio [HR], 0.521; 95% CI, 0.379-0.717). Similarly, patients with ≥2 risk factors in the BV arm experienced significantly higher PFS at 5 years than patients in the placebo arm (HR, 0.424; 95% CI, 0.302-0.596). Upfront consolidation with BV significantly delayed time to second subsequent therapy, an indicator of ongoing disease control, vs placebo. Peripheral neuropathy, the most common adverse event in patients receiving BV, continued to improve and/or resolve in 90% of patients. In summary, consolidation with BV in adult patients with cHL at high risk of relapse or progression after auto-HSCT confers a sustained PFS benefit and is safe and well tolerated. Physicians should consider each patient's HL risk factor profile when making treatment decisions. This trial was registered at www.clinicaltrials.gov as #NCT01100502. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|